Lung Cancer
Conference Coverage
Study identifies risk factors for infection after transbronchial biopsy
“The inflammation-prone status of lesions may be the most important factor” for developing infection after undergoing endobronchial ultrasound-...
News
Guidelines on delaying cancer surgery during COVID-19
The American College of Surgeons has issued new guidelines for cancer surgery in the era of COVID-19.
Opinion
Perspective from the heartland: Cancer care and research during a public health crisis
Dr. Alan P. Lyss examines how the COVID-19 pandemic has and will affect cancer care and research.
Latest News
Cancer care and COVID-19 in Seattle, the first U.S. epicenter
Feature
How is oncology adapting to COVID-19?
From the Journals
Carboplatin plus pemetrexed should be ‘a standard option’ in elderly patients with NSCLC
Performance status matters more than age in the treatment of patients with non–small cell lung cancer, a study suggests.
From the Journals
Doublet may be beneficial in wild-type, advanced NSCLC
About 77% of patients achieved a partial response or had stable disease on combination apatinib and vinorelbine.
From the Journals
Combo maintenance boosts PFS, not OS, in advanced NSCLC
Adding pemetrexed to bevacizumab maintenance improved progression-free survival but not overall survival.
From the Journals
Pembro ups survival in NSCLC: ‘Really extraordinary’ results
The 3-year overall survival rate was 35% in the entire cohort and 99% in patients who completed all treatment cycles.
From the Journals
Pembrolizumab plus chemoradiotherapy shows early promise in NSCLC
Researchers deemed the combination “feasible and well tolerated,” with a “promising” progression-free survival rate at 12 months.